UNCLASSIFIED Department of Defense Fiscal Year (FY) 2007 President's Budget February 2006 Research, Development, Test, and Evaluation, Defense-Wide Volume 4 Chemical Biological Defense Program (CBDP) UNCLASSIFIED THIS PAGE INTENTIONALLY LEFT BLANK Table of Contents DoD Joint Service Chemical and Biological Defense Program Fiscal Year (FY) 2007 Budget Request TABLE OF CONTENTS i CHEMICAL AND BIOLOGICAL DEFENSE PROGRAM RDT&E OVERVIEW iii R-1 EXHIBIT FOR CHEMICAL AND BIOLOGICAL DEFENSE PROGRAM vii BA1 - BASIC RESEARCH 1 BA2 - APPLIED RESEARCH 41 BA3 - ADVANCED TECHNOLOGY DEVELOPMENT (ATD) 131 BA4 - ADVANCED COMPONENT DEVELOPMENT AND PROTOTYPES (ACD&P) 217 BA5 - SYSTEM DEVELOPMENT AND DEMONSTRATION (SDD) 371 BA6 - RDT&E MGT SUPPORT 555 BA7 - OPERATIONAL SYSTEMS DEVELOPMENT 599 i THIS PAGE INTENTIONALLY LEFT BLANK ii Department of Defense Chemical/Biological Defense Program Overview Fiscal Year (FY) 2007 President's Budget The DoD Chemical and Biological (CB) Defense Program is a key part of a comprehensive national strategy to counter the threat of chemical and biological weapons as outlined in the National Strategy to Combat Weapons of Mass Destruction, December 2002. This national strategy is based on three principal pillars: (1) Counterproliferation to Combat WMD Use, (2) Strengthened Nonproliferation to Combat WMD Proliferation, and (3) Consequence Management to Respond to WMD Use. The DoD CB Defense Program (CBDP) provides research, development, and acquisition (RDA) programs primarily to support the first and third pillars. In support of counterproliferation, the DoD CBDP provides passive defenses tailored to the unique characteristics of the various chemical and biological weapons, including emerging threats. These capabilities provide U.S. forces the ability to rapidly and effectively mitigate the effects of a CB attack against our deployed forces. In support of counterproliferation, the DoD CBDP provides capabilities to respond to the effects of WMD use against our forces deployed abroad, and the homeland. The CBDP funds research to exploit leading edge technologies to ensure that U.S. forces are equipped with world class capabilities to defend against CB threats through the far term. This budget includes support of a comprehensive science and technology base program to ensure continued advances in CB defense capabilities. CBDP Basic Research provides core capabilities to ensure U.S. technological advantages through the far term, including research into advanced chemical and biological detection systems, advanced materials for improved filtration systems and protection systems, advanced decontaminants, investigations into the environmental fate of chemical warfare agents, advanced information technologies, medical biological defense research (including novel biodefense initiatives that focus on interrupting the disease cycle before and after exposure, as well as addressing the bioengineered threat), diagnostics, therapeutics, and vaccines for viral, bacterial, toxin, and novel threat agents), and medical chemical defense (including investigations of low level chemical warfare agent exposures, diagnostics, therapeutics, pretreatments for classical chemical warfare threats and novel threat agents). iii The CBDP also supports numerous Defense Technology Objectives (DTOs), which represent the key science and technology base programs for demonstrating advanced capabilities in the near and mid-term. During FY07, DTOs support operational capabilities to Sense (Reconnaissance, Detection and Identification), Shape (Battle Management), Shield (Individual & Collective Protection), and Sustain (Decontamination & Restoration) U.S. forces for passive defense, force protection, and consequence management missions. During FY07, the CBDP supports DTOs including capabilities for Environmental Fate of Nontraditional Agents, Low-Level Chemical Warfare Agent Exposure: Effects and Countermeasures, Chemical Warfare Agent Operational Exposure Hazard Assessment Research, Self-Detoxifying Materials for Chemical/Biological Protective Clothing, Advanced Air Purification System Model, Hazard Prediction with Nowcasting, Rapid Detection, Threat Assessment and Attribution of Genetically Engineered Biothreat Organisms Using Microarray-Based Resequencing Technologies, Methodology to Facilitate Development of Biological Warfare Threat Agent Detection and Medical Diagnostic Systems, Therapy for Smallpox and Other Pathogenic Orthopoxviruses, Western and Eastern Equine Encephalitis Vaccine Constructs for a Combined Equine Encephalitis Vaccine, Therapeutics for Ebola and Marburg Virus Infections, Lightweight Integrated Chemical/Biological Detection, and Multiagent (Molecular) Vaccines for Biowarfare Agents. Technologies currently Budget Activity 4 (Advanced Component Development and Prototypes) and Budget Activity 5 (System Development and Demonstration) provide leading edge tools that will enhance CB defense capabilities for U.S. forces in all CB defense missions in the near-term. As described in the National Strategy to Combat Weapons of Mass Destruction, the response to chemical and biological threats requires tailored approaches that recognize the fundamental differences between chemical and biological weapons (and even the different types of these threats). This budget details the comprehensive array of systems under development essential to support principles of contamination avoidance, protection, and decontamination. iv Key systems in Budget Activity 4 and Budget Activity 5 in FY07 include: the Joint Service Lightweight Standoff Chemical Agent Detector (JSLSCAD) for standoff chemical agent detection, Joint Chemical Agent Detector (JCAD) for portable point chemical agent detection, Joint Effects Model (JEM) and Joint Operational Effects Federation (JOEF) to provide risk management tools to the warfighter, Advanced Concept Technology Demonstrations (Chemical Biological Radiological Nuclear (CBRN) Unmanned Ground Reconnaissance (CUGR) and Situational Awareness and Response Network (STARNET)), Joint Service Transportable Decontamination System - Small Scale (JSTDS-SS), Joint Service Sensitive Equipment Decontamination (JSSED), Joint Service Personnel/Skin Decontamination System (JSPDS), Advanced Anticonvulsant System, Plasma and Recombinant Bioscavenger, Improved Nerve Agent Treatment System (INATS), biological defense vaccines (including recombinant botulinum vaccine and plague vaccine) as part of the Joint Vaccine Acquisition Program (JVAP), Critical Reagents Program (CRP) to support development of reagents for biological detection and diagnostic systems, Joint Biological Point Detection System (JBPDS), Joint Service Chemical/Biological/Radiological Agent Water Monitor (JCBRAWM), Joint Biological Standoff Detection System (JBSDS) Increment II, Joint Bio Tactical Detection System (JBTDS), Joint Biological Agent Identification and Diagnostic System (JBAIDS) Increment II, Joint Warning and Reporting Network (JWARN), Joint Collective Protection Equipment (JCPE), Joint Expeditionary Collective Protection, Joint Service Aircrew Mask (JSAM) and Medical Radiological Countermeasures. In FY07, the CBDP will start or continue procurement on a variety of CB defense systems intended to provide U.S. forces with the best available equipment to survive, fight, and win in CB contaminated environments. Systems beginning procurement in FY07 include JSPDS, JCAD, and JBAIDS Increment II. Systems continuing procurement in FY07 include Automatic Chemical Agent Detector and Alarm (ACADA), JSAM, Multi-Service Radiacs (MSR), Joint Service Transportable Decontamination System - Small Scale (JSTDS-SS), the Joint Effects Model (JEM), Joint Service General Purpose Mask (JSGPM), JWARN, JBAIDS, Joint Service Mask Leakage Tester (JSMLT), Joint Service Lightweight Integrated Suit Technology (JSLIST), the NBC Reconnaissance Vehicle (NBCRV), Joint Service Light NBC Reconnaissance System (JSLNBCRS), JSLSCAD, JBPDS, biological defense vaccines (Anthrax Vaccine Adsorbed), CB Protective Shelters (CBPS), Collective Protective Field Hospitals (CPFH), Collective Protection System Backfit (CPSBKFT), and chemical and biological defense equipment for installation force protection. v The FY07 program continues to support the consequence management (CM) mission. CM projects fund the development of the Unified Command Suite (UCS) and Analytical Laboratory System (ALS) Block upgrades. CM funding provides for the modernization to address objective operational capabilities for the National Guard WMD Civil Support Teams (CSTs), the Reserve Component (RC) Reconnaissance, and RC Decontamination Teams. It provides full funding for: (1) type-classified protection, detection, and training equipment; (2) development and fielding of upgraded analytical platforms for the detection, identification, and characterization of chemical, biological, and radiological agents used by terrorists in a civilian environment; (3) development and fielding of communication capabilities that are interoperable with other federal, state, and local agencies; (4) testing and evaluation to ensure that the systems fielded are safe and effective; and (5) program management funds. Overall, the FY 2007 President's Budget achieves a structured, executable, and integrated medical and non-medical joint CB Defense Program that balances urgent short-term procurement needs that include securing the homeland from terrorist attack, and long-term S&T efforts to mitigate future CB attacks. The primary area of increased emphasis in this year's